New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting.
Groth A, Salnikov AV, Ottinger S, Gladkich J, Liu L, Kallifatidis G, Salnikova O, Ryschich E, Giese N, Giese T, Momburg F, Büchler MW, Moldenhauer G, Herr I.
Groth A, et al. Among authors: ryschich e.
Clin Cancer Res. 2012 Feb 15;18(4):1028-38. doi: 10.1158/1078-0432.CCR-11-2767. Epub 2012 Jan 6.
Clin Cancer Res. 2012.
PMID: 22228630